AbbVie accused of anticompetitive tactics to stop Humira biosimilars

Home/Policies & Legislation | Posted 30/10/2020 post-comment0 Post your comment

Pharmaceutical manufacturer AbbVie faces another legal challenge related to anticompetitive tactics in the US. On 12 October 2020, the US Public Interest Research Group (US PIRG) filed an appeal accusing AbbVie of employing tactics that have delayed market entry of biosimilars.

24-AA011041

It is argued that biosimilar delayed market entry caused by AbbVie’s reverse payment settlements and creation of ‘patent thickets’ have costed American citizens billions of dollars. It is hoped that the outcome of this case will prevent further illegal abuses of the American patent system and deliver affordable treatment options to patients. The case was previously dismissed by the district court.

In a reverse payment – or pay-for-delay ‒ settlement, a patent holder pays a potential competitor not to sell their product for a period of time. This maintains originator monopoly and allows them to continue to charge high prices for drugs. A patent thicket is when a patent holder makes multiple, overlapping patents related to an originator product that work to extend its patent period.

It is alleged that AbbVie has used these anticompetitive practices to continually raise the price of Humira in the US. This is the world’s best-selling drug and is primarily used to treat rheumatoid arthritis. Its current price is US$72,000 per patient per year, which has more than tripled since 2006. However, biosimilars of Humira are available in Europe where AbbVie’s product can cost up to 80% less. The case’s brief states that in the US, Humira’s patent was due to expire in 2016, before it set up a patent ticket. When its competitors challenged this, they agreed to delay market entry until 2023 in exchange for earlier entry to the European market.

Related articles
Inter partes review and the generic drug industry

US policy brief identifies barriers to biosimilars uptake

Why does the US face high-priced generics and drug shortages?

Adalimumab copy biological shown to be safe and effective

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
Home/Policies & Legislation Posted 05/11/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010